Clinical Trial Update: Tislelizumab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With Advanced CRC [Phase 2]

View source ↗

Summary

Phase 2 trial investigating tislelizumab combined with fruquintinib and SBRT as third- to posterior-line therapy in advanced metastatic colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Fruquintinib (fruquintinib)
• SBRT (stereotactic body radiotherapy)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Huazhong University of Science and Technology | Conditions: Patients With Advanced Metastatic Colorectal Cancer | Phase 2 | Status: UNKNOWN